Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HINT1 | P49773 | 3/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473385 | 1.00 | HPGD (0.44) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL12851760 | 0.95 | HPGD (0.45) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL12851722 | 0.84 | ADORA3 (0.53) | HPGDHINT1ADORA3NT5ETAAR1 | |
| SCHEMBL12851761 | 0.83 | NT5E (0.37) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL12851698 | 0.83 | NT5E (0.37) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL26269037 | 0.83 | HINT1 (0.51) | HINT1ADORA3NT5ETAAR1STING1 | |
| SCHEMBL26269047 | 0.83 | HINT1 (0.51) | HINT1ADORA3NT5ETAAR1STING1 | |
| SCHEMBL15723521 | 0.83 | HPGD (0.39) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15070820 | 0.82 | HPGD (0.42) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL16473387 | 0.82 | HINT1 (0.36) | HPGDHINT1IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029335-B2 | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140106451-A1 | SUBSTITUTED 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140106451-A1 | SUBSTITUTED 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | HPGD 4082/4885HINT1 516/4885IMPDH2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.